吉林龟头发炎治疗的男科医院(吉林治疗阳痿哪家医院较好) (今日更新中)

NEW YORK, April 13 (Xinhua) -- New York City Mayor Michael Bloomberg and former U.S. President Bill Clinton announced on Wednesday the merger of their environmental groups, hoping to make it the most prominent climate policy organization in the world.The new organization would combine C40, a coalition of international cities run by Bloomberg, and the Clinton Climate Initiative, a project of Clinton' s philanthropic foundation, into a single organization, which will focus on population-rich cities to address global warming."I am elated by this. I think we really have a chance to make a difference," said Bill Clinton during a press conference at Gracie Mansion, adding that "together we are proving it is possible to create jobs and grow economies through reduced emissions."C40 and the Clinton Climate Initiative both seek to cut carbon emissions through programs that reduce energy use in buildings, promote mass transit and reuse greenhouse gases emitted by landfills.The newly combined organization is said to have a budget of about 15 million U.S. dollars. The group will have main offices in New York, Los Angeles and London.

NEW DELHI, March 5 (Xinhua) -- Doctors in India have claimed to have successfully performed a rare robotic heart surgery on a 23- year-old person at a hospital in the southern Indian city of Chennai, local media reported Saturday.Dr. R. Ravi Kumar, the Director of the Institute of Cardiovascular Disease at the Chettinad Health City, said the robotically assisted procedure involved replacing both the mitral and the aortal valve simultaneously.The surgery carried out on D. Vijayakanth, an auto driver from Vellore, was done by a three armed robot, took four hours and cost 225,000 rupees (4,500 U.S. dollars)."The best part about using a robot in cardiac surgery is that the patient's heart need not be opened and the surgery can be done using a small 4cm incision. This is not possible with normal surgeries without a robot," Dr Ravi Kumar was quoted by local daily The Times of India as saying.Robotic surgery, which is fairly new in the country, can be used for a gamut of medical procedures, said Dr Ravi Kumar."It requires a lot of precision and intense training because though the robotic hands do the surgery, it has to be controlled by a trained surgeon. One of the biggest disadvantages is the lack of sensory perception which is there when the surgeon actually does the surgery himself," he said.

BEIJING, Jan. 31 (Xinhua) -- Chinese Vice Premier Wang Qishan met in Beijing Monday with a delegation from the Geneva Association (GA), an insurance economics group, headed by chairman Nikolaus Von Bomhard.Wang hoped the GA board would hold a successful board meeting in Beijing, praising the positive role the organization played in promoting reform of the international insurance industry.China's insurance industry was undergoing rapid and profound changes and development, said Wang. He hoped the GA could work with Chinese insurance companies to jointly push forward the global development of the industry.Chinese Vice Premier Wang Qishan (R) meets with Nikolaus Von Bomhard, chairman of the Geneva Association (GA), an insurance economics group, in Beijing, capital of China, Jan. 31, 2011.Von Bomhard pledged the GA's commitment to stepping up exchanges and cooperation with the Chinese insurance sector.The Geneva Association describes itself as an international insurance "think tank" for strategically important insurance and risk management issues. It is the first time that the association has hosted a board meeting in an Asian country.

BEIJING, March 8 (Xinhuanet) -- U.S. Food and Drug Administration (FDA) announced there was no new reason for safety concern in Pfizer Inc's Prevenar and Sanofi Aventis SA's ActHIBor vaccines, according to media reports Tuesday.Health agencies "have not detected new safety concerns or unusual reporting patterns" in the vaccines, which are used to prevent forms of meningitis and pneumonia, FDA spokeswoman Shelly Burgess said in an emailed statement.Health agencies in the United States will continue to monitor the vaccines for safety, the spokeswoman added.The Japanese health ministry had decided to suspend the vaccines after four unexplained deaths were reported. The causes of the deaths are still investigated, the Japanese ministry said in a release on its website.

WASHINGTON, March 24 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Thursday approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.In the United States shingles affects approximately 200,000 healthy people between the ages of 50 and 59, per year. It is a disease caused by the varicella-zoster virus, which is a virus in the herpes family and the same virus that causes chickenpox.After an attack of chickenpox, the virus lies dormant in certain nerves in the body. For reasons that are not fully understood, the virus can reappear in the form of shingles, more commonly in people with weakened immune systems and with aging."The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease" said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement. ( Shingles is characterized by a rash of blisters, which generally develop in a band on one side of the body and can cause severe pain that may last for weeks, and in some people, for months or years after the episode.Approval was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.The most common side effects observed in the study were redness, pain and swelling at the site of injection, and headache, according to the FDA.Zostavax, manufactured by Merck & Co., was originally approved on May 26, 2006, for the prevention of shingles in individuals 60 years of age and older.

来源：资阳报